Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
出版年份 2021 全文链接
标题
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
作者
关键词
-
出版物
ESMO Open
Volume 6, Issue 6, Pages 100293
出版商
Elsevier BV
发表日期
2021-10-22
DOI
10.1016/j.esmoop.2021.100293
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
- (2020) Chiara Cremolini et al. LANCET ONCOLOGY
- Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial
- (2020) Gita Thanarajasingam et al. Lancet Haematology
- Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
- (2020) Chiara Cremolini et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study
- (2019) Takatsugu Ogata et al. Oncotarget
- Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update
- (2018) Randy A. Taplitz et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
- (2018) Hironaga Satake et al. Oncotarget
- DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
- (2017) Chiara Cremolini et al. Oncotarget
- FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
- (2016) C. Cremolini et al. ANNALS OF ONCOLOGY
- Management of febrile neutropaenia: ESMO Clinical Practice Guidelines†
- (2016) J. Klastersky et al. ANNALS OF ONCOLOGY
- DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
- (2015) Felicia Stefania Falvella et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. Targeted Oncology
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
- (2010) Matti Aapro et al. SUPPORTIVE CARE IN CANCER
- Advances in the treatment of neutropenia
- (2009) David C Dale Current Opinion in Supportive and Palliative Care
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started